A. Albasanz-Puig Et Al. , "Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a PropensityMatched Cohort Study (AMINOLACTAM Study)," ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , vol.65, no.8, 2021
Albasanz-Puig, A. Et Al. 2021. Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a PropensityMatched Cohort Study (AMINOLACTAM Study). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , vol.65, no.8 .
Albasanz-Puig, A., Gudiol, C., Puerta-Alcalde, P., Ayaz, C. M., Machado, M., Herrera, F., ... Martin-Davila, P.(2021). Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a PropensityMatched Cohort Study (AMINOLACTAM Study). ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , vol.65, no.8.
Albasanz-Puig, A. Et Al. "Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a PropensityMatched Cohort Study (AMINOLACTAM Study)," ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , vol.65, no.8, 2021
Albasanz-Puig, A. Et Al. "Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a PropensityMatched Cohort Study (AMINOLACTAM Study)." ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , vol.65, no.8, 2021
Albasanz-Puig, A. Et Al. (2021) . "Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a PropensityMatched Cohort Study (AMINOLACTAM Study)." ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , vol.65, no.8.
@article{article, author={A. Albasanz-Puig Et Al. }, title={Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a PropensityMatched Cohort Study (AMINOLACTAM Study)}, journal={ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}, year=2021}